Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Viridian Therapeutics (VRDN) and Definitive Healthcare Corp (DH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA – Research ...
Hosted on MSN2d
FDA removes clinical hold on Entrada’s Duchenne therapy
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
FierceBiotech3d
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Received FDA authorization to initiate ELEVATE-44-102 in the U.S. –– Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. –– ...
Hosted on MSN1d
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.29 per share a ...
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have ...
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...
Entrada Shares Climb After FDA Removes Hold on Muscular Dystrophy Treatment
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Summit County17d
Breckenridge affordable housing project moves on to next steps after getting the OK from planning officials
The last-minute addition to one of Breckenridge’s largest developments was pushed forward to a final review by planning ...
Calvin College1y
Entrada Scholars Program
Entrada is a four-week program for students of color in grades 11 and 12. You’ll learn like a university student, live in the dorms, and earn college credit. Entrada students earn $6,000–$10,000 in ...